SE‑Cluster

Search

Search markets, companies, evidence, and pages

readymarket review3 sections8 citations

Q2 2026 Life Sciences Tools, Diagnostics & MedTech market review

Life Sciences Tools, Diagnostics & MedTech is cooling this window, with 182 buys in the last 3 years vs 234 prior across 155 public acquirers.

Generated May 26, 2026, 10:49 PMSource packet: market reviewSE-Cluster evidence packet

Client preview

Print and copy from the deliverable view.

Market thesis

[1][2]
2 cites
Priority buyers pair regulatory know-how and commercial channels with repeat acquisitions that fill product, testing, or workflow gaps.

[1] 10-K· 2026-02-26

FY 2023 strategy language. The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces.

[2] 10-K· 2026-02-26

FY 2023 strategy language. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.

Buyer hierarchy

[1][2][3]
3 cites
TMO, BDX, BSX, LH, TFX lead the current buyer hierarchy with 1,334 recorded buys among ranked acquirers.

[1] 10-K· 2026-02-26

FY 2023 strategy language. The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces.

[2] 10-K· 2026-02-26

FY 2023 strategy language. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.

[3] 10-K· 2026-02-26

FY 2019 strategy language. The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses.

Filing signals

[4][5][6][7]
4 cites
Boston Scientific Corp.: 57 recorded buyer-side acquisition reference(s); filings read as very active buyer activity. Teleflex Incorporated: 52 recorded buyer-side acquisition reference(s); filings read as very active buyer activity. Integra Lifesciences Holdings Corp.: 52 recorded buyer-side acquisition reference(s); filings read as very active buyer activity. Danaher Corp.: 149 recorded buyer-side acquisition reference(s); filings read as very active buyer activity. Revvity, Inc.: 59 recorded buyer-side acquisition reference(s); filings read as very active buyer activity.

[4] 10-K

FY 2025 strategy language. We believe that our products and solutions compete primarily on their ability to deliver both differentiated clinical and economic outcomes for our customers by enabling physicians to perform diagnostic and therapeutic procedures safely and effectively often in a less-invasive and cost effective manner.

[5] 10-K

FY 2024 strategy language. We believe that our products and solutions compete primarily on their ability to deliver both differentiated clinical and economic outcomes for our customers by enabling physicians to perform diagnostic and therapeutic procedures safely and effectively often in a less-invasive and cost effective manner.

[6] 10-K

FY 2024 strategy language. In the current environment of managed care, with economically motivated buyers, consolidation among health care providers, increasing prevalence and importance of regional and national tenders, increased competition and declining reimbursement rates, we are also required to compete on the basis of price, value, reliability and efficiency.

[7] 10-K· 2026-02-27

FY 2023 strategy language. We may not be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions, and may experience business disruptions associated with restructuring, facility consolidations, realignment, cost reduction and other strategic initiatives.